FDA & Government News

FDA Okays Weekly Option in Achondroplasia

Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.

Share

  • 1

    Navepegritide approved by FDA for growth in achondroplasia.

  • 2

    Target age: 2 years and older.

  • 3

    Improves annualized growth velocity.

  • 4

    Rare Pediatric Disease Priority Review Voucher issued.

  • 5

    Potential complications include spinal issues and muscular problems.

  • 6

    Injection site reactions are common adverse effects.

  • 7

    Commercial launch expected by Q2 2026.

Original Source(s)

FDA Okays Weekly Option in Achondroplasia

Navepegritide is described as the first therapy to deliver continuous C-type natriuretic peptide exposure over a weekly dosing interval in eligible pediatric patients.

  • by Kathryn Wighton

  • March 2, 2026

  • 2 min

Related Content

Youth Obesity Reaches 20% in US

New data from over 6 million children reveal persistent weight disparities across age and racial groups.

Unusual Neonatal Presentation of 48,XXYY

Dual presentation expands known phenotypic spectrum of the syndrome

Vaccine Playbook Rewrite: Who’s In Charge?

HHS Secretary Robert F. Kennedy Jr.’s changes at the CDC are prompting states and medical societies to issue independent vaccine recommendations, challenging long-standing national immunization policy.